Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab 2 mL Auto-injector in Plaque Psoriasis
NCT03589885Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Dec 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03589885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589885.